Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 2, 2000, Pages 100-103

  Inoue, Akiko ^a   Wada, Hideo ^a   Takagi, Mikio ^b   Yamamuro, Miho ^a   Mukai, Kenji ^b   Nakasaki, Takahiro ^a   Shimura, Minori ^a   Hiyoyama, Kazuyo ^a   Deguchi, Hiroshi ^a   Gabazza, Esteban C ^a   Mori, Yoshitaka ^a   Nishikawa, Masakatsu ^a   Deguchi, Katsumi ^b   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ise General Hospital   (Japan)

Author keywords

Hemodialysis; PC; TF; Thrombotic complication

Indexed keywords

ANTIPLASMIN; PLASMIN; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; DIABETES MELLITUS; DIALYSIS; FEMALE; GLOMERULONEPHRITIS; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOSTASIS; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOSIS;

EID: 17544402800     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600210     Document Type: Article

References (29)

1. Bruton BT, Kruegar KK, Bryan FA: National registry of longterm dialysis patients. JAMA 1971;218:718.
2. Brunner FP, Brynger H, Chantier C, et al. Combined report on regular dialysis and transplantation in Europe IX, 1978. In Proceedings of the European Dialysis and Transplant Association, XVI edn. Robinson BHB, Howkins JB, Naik RB (eds.) Bath, UK: Pitman Medical; 1979:7.
3. Deguchi K, Izumi K, Noguchi M, et al. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis. Acta Haematol Jpn 1989;52:140.
4. Takagi M, Wada H, Mukai K, et al. Increased vascular endothelial cell markers in patients with chronic renal failure on maintenance haemodialysis. Blood Coag Fibr 1994;5:713.
5. Tomura S, Nakamura Y, Deguchi F, et al. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990;58:413.
6. Nemerson Y, Bach R. Tissue factor revisited. Prog Hemost 1982; 6:237.
7. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991;66:6.
8. Shimura M, Wada H, Wakita Y, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;52:165.
9. Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1987;59:101.
10. Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor. Blood 1987;69:446.
11. Marlar RA, Endres-Brook J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated in travascular coagulation. Blood 1985;66:59.
12. Asakura H, Saito M, Ito K, et al. Levels of thrombin-antithrombin III complex in plasma in cases of acute promyelocytic leukemia. Thromb Res 1988;50:895.
13. Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombocytopenic purpura patients with severe vascular injuries. Am J Hematol 1998;58:189.
14. Abumiya T, Enjyoji K, Kokawa T, et al. An anti-tissue factor pathway inhibitor(TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995;118:178.
15. Kokawa T, Enjyoji K, Kumeda K, et al. Measurement of the free form of TFPI antigen in hyperlipidemia: Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996;16:802.
16. Kamei S, Kamikubo Y, Hamuro T, et al. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem 1994;115: 708.
17. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1.
18. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988;71:629.
19. Rodgers GM. Hemostatic properties of normal and perturbed vascular cells. Fed Am Soc Exp Biol J 1988;1:116.
20. Sandset PM, Hagevold HE, Lyberg T, et al. Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thromb Haemost 1989;62:856.
21. Novotny WF, Palmier M, Wun T-C, et al. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991;78:394.
22. Kamikura Y, Wada H, Yamada A, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997;55:183.
23. Rickles FR, Rick PD, Van Why M: Structural features of S. typbimurium lipopolysaccharide required for activation of monocyte tissue factor. J Clin Invest 1977;59:1188.
24. Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cell generation tissue factor in response to endotoxin. J Clin Invest 1983;71:1983.
25. Schorer AE, Kaplan ME, Rao GHR, Moldow CF. Interleukin-1 stimulated endothelial tissue factor production and expression by a prostaglandin-independent mechanism. Thromb Haemost 1987;56: 256.
26. Bevilacqua MP, Prober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533.
27. Tannenbaum SH, Finko R, Cines DB: Antibody and immune complexes induce tissue factor production in human endothelial cells. J Immunol 1986;137:1532.
28. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987;235:1348.
29. Broekmana AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thrombo-embolism: a study of three Dutch families. N Engl J Med 1983;309:340.